VIR BIOTECHNOLOGY INC (VIR) — insider trading
Health Care · NASDAQ
VIR BIOTECHNOLOGY INC (VIR) has 25 reported SEC Form 4 insider transactions in our data, including 5 open-market sales among the most recent 25 (latest 2026-08-11).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-11 | MORE ROBERT J | Director | Other acquisition or disposition | 8,000 | — | $0 | Form 4 |
| 2026-08-11 | MORE ROBERT J | Director | Other acquisition or disposition | 8,000 | — | $0 | Form 4 |
| 2026-06-09 | Coughlin Timothy | Director | Grant / award / vesting (derivative) | 16,000 | — | $0 | Form 4 |
| 2026-06-09 | Coughlin Timothy | Director | Grant / award / vesting (derivative) | 16,000 | — | $0 | Form 4 |
| 2026-06-09 | Coughlin Timothy | Director | Grant / award / vesting | 8,000 | — | $0 | Form 4 |
| 2026-06-09 | Coughlin Timothy | Director | Grant / award / vesting | 8,000 | — | $0 | Form 4 |
| 2026-06-01 | Sabatini Brent | Officer (SVP, Chief Accounting Officer) | Open-market sale | 379 | $9.45 | $3.6K | Form 4 |
| 2026-06-01 | Napolitano Janet | Director | Open-market sale | 3,200 | $9.45 | $30.2K | Form 4 |
| 2026-05-27 | BISCHOFBERGER NORBERT W | Director | Grant / award / vesting (derivative) | 16,000 | — | $0 | Form 4 |
| 2026-05-27 | BISCHOFBERGER NORBERT W | Director | Grant / award / vesting | 8,000 | — | $0 | Form 4 |
| 2026-05-27 | Farid Ramy | Director | Grant / award / vesting (derivative) | 16,000 | — | $0 | Form 4 |
| 2026-05-27 | Farid Ramy | Director | Grant / award / vesting | 8,000 | — | $0 | Form 4 |
| 2026-05-27 | Hatfield Jeffrey S. | Director | Grant / award / vesting (derivative) | 16,000 | — | $0 | Form 4 |
| 2026-05-27 | Hatfield Jeffrey S. | Director | Grant / award / vesting | 8,000 | — | $0 | Form 4 |
| 2026-05-27 | MORE ROBERT J | Director | Grant / award / vesting (derivative) | 16,000 | — | $0 | Form 4 |
| 2026-05-27 | MORE ROBERT J | Director | Grant / award / vesting | 8,000 | — | $0 | Form 4 |
| 2026-05-27 | Napolitano Janet | Director | Grant / award / vesting (derivative) | 16,000 | — | $0 | Form 4 |
| 2026-05-27 | Napolitano Janet | Director | Grant / award / vesting | 8,000 | — | $0 | Form 4 |
| 2026-05-27 | Sigal Charles Elliott | Director | Grant / award / vesting (derivative) | 16,000 | — | $0 | Form 4 |
| 2026-05-27 | Sigal Charles Elliott | Director | Grant / award / vesting | 8,000 | — | $0 | Form 4 |
| 2026-05-01 | SATO VICKI L | Director | Open-market sale | 22,000 | $10.05 | $221.0K | Form 4 |
| 2026-04-29 | De Backer Marianne | Director, Officer (President and CEO) | Other acquisition or disposition | 233,532 | — | $0 | Form 4 |
| 2026-04-29 | De Backer Marianne | Director, Officer (President and CEO) | Other acquisition or disposition | 233,532 | — | $0 | Form 4 |
| 2026-04-06 | De Backer Marianne | Director, Officer (President and CEO) | Open-market sale | 72,559 | $9.16 | $664.4K | Form 4 |
| 2026-04-01 | SATO VICKI L | Director | Open-market sale | 22,000 | $9.07 | $199.6K | Form 4 |
Ask the chat about VIR's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: VIR BIOTECHNOLOGY INC (VIR).
Last updated 2026-08-11 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.